Obesity and breast cancer recurrence: an interview with Dr. Joseph Sparano
Breast cancer recurrence is a major problem after treatment of localized breast cancer. The risk of recurrence depends on several factors including the stage of presentation and the biology of the...
View ArticleStudy shows increased risk of local recurrence in women with triple negative...
Research from The Cancer Institute of New Jersey (CINJ) shows that women with triple-negative breast cancer and no more than three positive lymph nodes following a mastectomy have a higher risk of...
View ArticleMost triple-negative breast cancer patients have multiple genetic mutations...
Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by...
View ArticleAggressive breast cancer’s metastasis molecular switch identified
Scientists at Weill Cornell Medical College have discovered the molecular switch that allows aggressive triple negative breast cancer cells to grow the amoeba-like protrusions they need to crawl away...
View ArticleTwo discriminating biological markers found to predict a favorable response...
Quinten, a strategic and operational consulting company specializing in the evaluation of biomedical data in the pharmaceutical, biotechnology and cosmetic industries, today announces the...
View ArticleSubcutaneous administration of Herceptin preferred by HER2-positive breast...
Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC...
View ArticleNew data highlights molecular profiling in guiding treatment of patients with...
Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data from studies demonstrating the potential...
View ArticleOxis Biotech executes licensing agreement with MCIT for development of...
Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc....
View ArticleScientists create universal assembly method to enhance cancer therapy and...
Biophysicists have developed a method for modifying the surface of micro- and nanoparticles — tiny structures measuring between a thousandth and a millionth of a millimeter — by covering them with...
View ArticleStudy demonstrates safety of novel immuno-oncology therapy in patients with...
A novel therapy designed to help stimulate the body's immune system response against cancer appears to be safe to use as alone or in combination with immune checkpoint inhibitors.
View Article
